Clinically aggressive pseudomyxoma peritonei: A variant of a histologically indolent process
Authors:
- Sue GethingSGSue Gething
- Paul H. SugarbakerPSPaul H. Sugarbaker
- 22 March 2004
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 86 (1) , 10-15
Abstract
Background Three distinct morphologic types of pseudomyxoma peritonei syndrome have been defined: disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinoma (PMCA), and a hybrid morphologic type. Prognosis is best in patients with DPAM; unfortunately, some patients with DPAM succumb to a rapidly progressive disease process. Methods We identified a subset of 11 patients with a histopathology of DPAM but a clinical course showing an invasive disease process. As a comparison group, from a database of 501 patients with pseudomyxoma peritonei, we selected 22 age‐ and sex‐matched controls with a DPAM histology who are alive with no evidence of disease. Clinical factors were identified for comparison of case and control groups. Expression of mucin antigens, mucin (MUC)1 and MUC2, were evaluated using immunohistochemistry. Results The study group consisted of 11 patients (five men and six women), with a median survival of 52.2 months (SD 7.46) and a 31% 5‐year survival. All 22 matched control cases (10 men and 12 women) are alive and disease‐free. Clinical data on the study and control groups including co‐morbidity were similar. No significant difference in the expression of MUC1 (P = 0.74, Fisher's exact test) or MUC2 (P = 0.34, Fisher's exact test) was demonstrated between groups. Conclusions Further investigation of pseudomyxoma peritonei at a molecular and genetic level may help to formulate a more comprehensive classification. J. Surg. Oncol. 2004;86:10–15.Keywords
This publication has 11 references indexed in Scilit:
- Pseudomyxoma Peritonei Is a Disease of MUC2-Expressing Goblet CellsThe American Journal of Pathology, 2002
- Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosisCancer, 2001
- Histopathologic Analysis in 46 Patients with Pseudomyxoma Peritonei Syndrome: Failure versus Success with a Second-Look OperationLaboratory Investigation, 2001
- MUC-1 expression as a predictor of the curative endoscopic treatment of submucosally invasive colorectal carcinomaDiseases of the Colon & Rectum, 1998
- Immunoreactive MUC1 Expression at the Deepest Invasive Portion Correlates with Prognosis of Colorectal CancerOncology, 1998
- Expression of mucin antigens in human cancers and its relationship with malignancy potentialPathology International, 1997
- Significance of MUC1 and MUC2 mucin expression in colorectal cancer.Journal of Clinical Pathology, 1996
- A Clinicopathologic Analysis of 109 Cases with Emphasis on Distinguishing Pathologic Features, Site of Origin, Prognosis, and Relationship to “Pseudomyxoma Peritonei”American Journal of Surgical Pathology, 1995
- Prognostic Features of 51 Colorectal and 130 Appendiceal Cancer Patients with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal ChemotherapyAnnals of Surgery, 1995
- Peritonectomy ProceduresAnnals of Surgery, 1995